Octave Bioscience Strengthens Precision Neurology Strategy with Appointment of Zachary Fernandes as Vice President of Business Development
Octave Bioscience, a commercial-stage precision medicine company dedicated to advancing biomarker-driven solutions for multiple sclerosis (MS), Parkinson’s disease, and other neurodegenerative disorders, has announced the appointment of Zachary Fernandes as its new Vice President of Business Development. The strategic leadership addition comes at a pivotal stage in the company’s growth as it expands its portfolio of innovative diagnostic technologies and strengthens collaborations across the healthcare and life sciences sectors.
In his new role, Fernandes will oversee Octave’s global business development and partnership initiatives, focusing on creating long-term strategic alliances that accelerate commercial growth, expand market reach, and support the company’s mission of transforming neurological disease management through precision medicine. His appointment reflects Octave’s commitment to building a robust ecosystem of partnerships with pharmaceutical companies, healthcare providers, diagnostic laboratories, research organizations, and technology innovators.
Fernandes joins Octave Bioscience with more than 15 years of experience in specialty diagnostics and healthcare business development. Throughout his career, he has established a reputation for building high-impact partnerships, launching innovative diagnostic programs, and driving commercial expansion in both public and private healthcare companies. His extensive background in neurodegenerative disease diagnostics and precision medicine aligns closely with Octave’s vision of delivering personalized, data-driven insights that improve patient outcomes.
Prior to joining Octave, Fernandes served as General Manager of Lucent Diagnostics at Quanterix Corporation, where he played a central role in developing and scaling the company’s diagnostic business. During his tenure, he helped drive adoption of a blood-based Alzheimer’s disease test among healthcare providers and major health systems, demonstrating the growing role of biomarker-based diagnostics in neurological care. His leadership contributed to expanding access to innovative testing solutions that support earlier detection and more informed clinical decision-making for patients affected by neurodegenerative diseases.
One of Fernandes’ notable achievements at Quanterix was leading the strategic partnership between Quanterix and Tempus, a collaboration designed to advance precision diagnostics and broaden access to cutting-edge healthcare technologies. The partnership underscored his ability to identify synergistic opportunities and establish alliances that create value for patients, clinicians, and industry stakeholders alike.
Before leading Lucent Diagnostics, Fernandes held the position of Vice President of Simoa Diagnostics, where he successfully negotiated and implemented multiple In Vitro Diagnostic (IVD) partnerships across key Asia-Pacific markets. His work included collaborations in Singapore, South Korea, and China, regions that represent some of the fastest-growing healthcare and diagnostics markets in the world. These initiatives helped strengthen commercial infrastructure, increase market penetration, and establish strategic pathways for introducing innovative diagnostic solutions to new patient populations.
Fernandes’ career also includes senior leadership positions at Mission Bio, Saphetor, and Veritas Genetics. Across these organizations, he consistently demonstrated expertise in developing business strategies, launching new commercial operations, and fostering partnerships that support sustainable growth. At Veritas Genetics, he was instrumental in establishing and scaling the company’s European business unit, guiding its development from an early-stage operation into a significant source of recurring annual revenue. His achievements highlight his ability to translate innovative scientific technologies into commercially successful healthcare solutions.
Throughout his professional journey, Fernandes has worked extensively with pharmaceutical companies, specialty diagnostics organizations, laboratory networks, and biotechnology firms. His experience spans the full spectrum of partnership development, including licensing agreements, market access initiatives, commercialization strategies, research collaborations, and global distribution partnerships. This broad expertise positions him well to support Octave Bioscience’s next phase of growth as the company expands its influence within the precision neurology landscape.
According to Octave Bioscience Chief Executive Officer Doug Biehn, the company’s timing in bringing Fernandes on board could not be better. Octave has experienced increasing momentum through adoption of its Multiple Sclerosis Disease Activity (MSDA) test, a biomarker-driven solution designed to provide objective insights into disease activity and progression. As healthcare providers increasingly seek tools that enable more personalized treatment decisions, Octave’s technology has gained recognition for delivering clinically meaningful data that can help guide patient management.
Biehn emphasized that Fernandes’ background in precision diagnostics and strategic partnerships will play an important role as the company prepares for another major milestone: the launch of its multi-analyte blood test for Parkinson’s disease later this year. The anticipated launch represents a significant expansion of Octave’s neurology portfolio and reflects the company’s broader ambition to address unmet needs across neurodegenerative disease care.
“Zac joins us at a perfect inflection point,” Biehn said. “Our MSDA test continues to gain traction among physicians while also delivering valuable biological insights to pharmaceutical partners. As we prepare to introduce our Parkinson’s blood-based testing platform, Zac’s experience building category-defining diagnostics businesses and cultivating transformative partnerships worldwide will be invaluable. His leadership will help accelerate our mission of improving care for people living with neurological diseases.”
For Fernandes, joining Octave represents an opportunity to contribute to a rapidly evolving field where scientific innovation is increasingly transforming patient care. He noted that his career has been shaped by a commitment to advancing diagnostics for neurodegenerative disorders and that Octave’s technology platform stands out for its clinical validation and practical utility.
“Precision neurology is entering an exciting new era,” Fernandes said. “The ability to measure disease biology through biomarkers is fundamentally changing how clinicians diagnose, monitor, and manage neurological conditions. Throughout my career, I have witnessed firsthand how innovative diagnostic tools can improve patient outcomes and support more informed treatment decisions. Octave has built a powerful platform backed by strong clinical evidence, and I am excited to help expand its impact.”
He added that the company’s focus on delivering objective, actionable insights aligns with the growing need for precision medicine approaches in neurology. By forging new partnerships and strengthening existing collaborations, Fernandes aims to accelerate adoption of Octave’s testing solutions while helping bring advanced diagnostic capabilities to healthcare providers and patients around the world.
The appointment comes at a time when the healthcare industry is placing greater emphasis on personalized medicine and biomarker-based diagnostics. Neurological disorders such as multiple sclerosis and Parkinson’s disease often present significant diagnostic and treatment challenges due to their complexity and variability among patients. Traditional assessment methods frequently rely on clinical observations and imaging studies, which may not always provide a complete picture of disease activity. Biomarker-driven testing offers the potential to supplement these approaches by providing objective measurements that can support earlier intervention, more precise treatment selection, and improved disease monitoring.
Octave Bioscience has positioned itself at the forefront of this transformation by developing advanced testing solutions designed specifically for neurological diseases. The company’s technologies integrate biomarker analysis with sophisticated data interpretation tools to deliver insights that help clinicians make more informed decisions throughout a patient’s care journey. By enabling a more personalized understanding of disease activity and progression, Octave aims to improve outcomes while reducing uncertainty in clinical management.
In addition to its work in multiple sclerosis, the company has expanded its focus to Parkinson’s disease through a collaboration with the Michael J. Fox Foundation, one of the world’s leading organizations dedicated to Parkinson’s research and advocacy. The partnership reflects a shared commitment to accelerating scientific progress and improving care for individuals living with Parkinson’s disease. Octave’s forthcoming multi-analyte blood test is expected to further strengthen its position as a leader in precision neurology and provide new opportunities for collaboration with researchers, healthcare systems, and pharmaceutical companies.
As Octave Bioscience continues to scale its commercial operations and broaden its reach within the healthcare ecosystem, the addition of Zachary Fernandes marks an important step in executing the company’s long-term growth strategy. His extensive experience in diagnostics commercialization, international market development, and strategic alliance management is expected to help drive new opportunities that expand access to innovative neurological testing solutions.
With increasing physician adoption of its MSDA platform, the upcoming launch of a Parkinson’s blood-based diagnostic test, and a growing network of industry partnerships, Octave Bioscience is entering a period of significant expansion. The company believes that combining cutting-edge biomarker science with strong strategic collaborations will be essential to advancing precision medicine and improving outcomes for millions of patients affected by neurological diseases worldwide.
As the field of precision neurology continues to evolve, Octave Bioscience’s leadership team remains focused on delivering innovative technologies that empower clinicians, support research efforts, and ultimately improve the lives of patients. Fernandes’ appointment reinforces that commitment and signals the company’s determination to build a future where neurological diseases can be diagnosed, monitored, and treated with greater accuracy and confidence than ever before.
About Octave Bioscience, Inc.
Octave Bioscience, Inc. is a commercial growth stage precision medicine company pioneering biomarker-driven solutions for neurodegenerative diseases, with an initial focus on Multiple Sclerosis, and Parkinson’s Disease in partnership with the Michael J. Fox Foundation. Octave’s comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes.
